There is a simple version of the GLP-1 business story.
Demand exploded, entrepreneurs noticed, and companies rushed to participate.
Derik Fay is betting on a more complicated version.
His thesis is that medications may create the demand, but infrastructure will determine which businesses remain valuable when the market matures.
That idea has brought Fay back into the CEO seat after several years spent primarily advising, investing and working around mergers and acquisitions.
The return is notable because Fay had already moved into a different phase of his career.
Through 3F Management, which he founded in 2004, Fay had spent more than two decades building and investing across industries including fitness, payments, financial services, marketing, technology and consumer businesses.
Company materials describe a history of more than 30 businesses built, scaled or exited.
One of the most visible was Around the Clock Fitness.
Fay founded the company in 2006, expanded it in Florida and ultimately sold the business to publicly traded Town Sports International Holdings in 2019.
Afterward, he did not immediately repeat the process.
His work increasingly moved toward corporate strategy, acquisitions and advising executive teams.
That period appears to have changed what he looks for in a new company.
The attraction of RX Management Systems was not simply that GLP-1 medications had become popular.
It was that the growth surrounding them exposed a collection of unresolved problems.
Payment processing.
Banking.
Pharmacy operations.
Licensing.
Fulfillment.
Compliance.
Technology.
Acquisitions.
Each individual function already existed.
The opportunity, in Fay’s view, was connecting them in a more scalable operating structure.
That is why RX Management Systems is organized as a management platform.
Believe RX provides a pharmacy component through its Texas-based 503A operation. Specialty Care oversees fulfillment and logistics. RX Management Systems sits above those functions with responsibility for growth, pharmacy relationships, compliance, management services and acquisitions.
The strategy reflects a theme that has followed Fay throughout his career.
He tends to focus less on the visible product and more on the system producing it.
In fitness, the customer saw a gym.
Behind the gym was real estate, operations, membership economics, staffing, systems and expansion strategy.
In payments, the consumer sees a transaction.
Behind that transaction are banks, merchant accounts, underwriting, risk controls and settlement infrastructure.
Healthcare works the same way.
The patient sees the medication.
The business sees everything that has to happen before and after the prescription.
That is why the fintech component of Fay’s background matters.
It does not mean RX Management Systems is becoming a financial technology company.
It means Fay has experience in an industry where the infrastructure underneath a transaction can become as strategically important as the transaction itself.
GLP-1 healthcare is beginning to show similar characteristics.
Financial institutions must determine which operators they are comfortable banking and processing.
Pharmacy businesses must operate inside increasingly scrutinized regulatory frameworks.
Providers and fulfillment organizations must coordinate across a fragmented system.
For Fay, those challenges are not separate from the opportunity.
They are the opportunity.
His M&A background adds another dimension.
Fay has described his operating philosophy as “dirt to exit,” meaning a company should be designed with its eventual enterprise value in mind from the beginning.
That approach forces different questions.
Is the revenue recurring?
Can the business operate without the founder?
Are the systems defensible?
Can it survive regulatory change?
Can an acquisition be integrated without disrupting everything around it?
Would an institutional buyer understand the structure?
Those questions are particularly relevant in a market where today’s most popular treatment may not be tomorrow’s.
Fay has repeatedly emphasized that medications change.
That matters.
A company whose value depends entirely on one product can become vulnerable when regulation, competition or consumer preferences move.
Infrastructure can be more adaptable.
The pharmacy can support different therapies.
The fulfillment system can process different prescriptions.
Compliance infrastructure can support different regulatory requirements.
Management services can extend across acquisitions and partnerships.
Payments remain necessary regardless of which medication happens to dominate the market.
That is the larger entrepreneurial bet behind RX Management Systems.
Fay is not simply trying to predict which drug wins.
He is trying to build something that still matters after the market decides.
That approach also explains his emphasis on reputation.
Healthcare companies do not operate alone.
They need pharmacy partners, banks, payment processors, vendors, regulators, acquisition targets and potentially institutional investors to become comfortable doing business with them.
Fay enters the category with decades of operating and transaction history behind him.
In a young industry, that history can become part of the asset.
Growth attracts attention.
Credibility attracts counterparties.
The next several years will determine which GLP-1 and peptide businesses turn rapid demand into durable companies.
Some will remain product businesses.
Some will disappear.
Others may evolve into infrastructure.
Derik Fay is building for the third outcome.
The GLP-1 boom may have given him the reason to return to operating.
What he is actually building appears intended to survive well beyond the boom.
